Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
Commentary|Articles|August 4, 2026
OS Wins, New Approvals, and Practice-Changing Data: Breaking Down the Biggest NSCLC News From ASCO 2026
Author(s)Caroline Seymour
Fact checked by: Kyle Doherty
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Advertisement
Advertisement
As data emerged across the non–small cell lung cancer (NSCLC) space at the
Related to this article
The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain
Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.
Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.
Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
Advertisement
Advertisement